Direct radioimmunoassay for haloperidol in human serum.
A direct radioimmunoassay for the accurate determination of haloperidol in human serum has been developed. Based on recent information about the metabolism of haloperidol, a new haloperidol hapten, in which a (3-carboxypropionyl)methylamino group was attached as a bridge in the place of fluorine atom, was synthesized and coupled to bovine serum albumin through the bridge to provide a new immunogen. Guinea pigs were used for the immunization. Since the antisera obtained by the new immunogen still cross reacted greater than 10% with reduced haloperidol, the immunological tolerance to reduced haloperidol was induced by administration of a copolymer of D-glutamic acid and D-lysine linked with reduced haloperidol. This gave an antiserum in guinea pigs which was highly specific for unchanged haloperidol with negligible cross reactivity (less than or equal to 1.0%) to any haloperidol metabolites including the newly found ones. With the newly developed antiserum and [3H]haloperidol, serum haloperidol levels can be determined over the concentration range from 0.3 to 20 ng/mL, using 0.1 mL of human serum, without an extraction procedure.
Terauchi
Y
Y
Research Laboratories, Dainippon Pharmaceutical Company, Ltd., Osaka, Japan.
Ishikawa
S
S
Oida
S
S
Nakao
M
M
Kagemoto
A
A
Oida
T
T
Utsui
Y
Y
Sekine
Y
Y
D000818:Animals; D002849:Chromatography, Gas; D003429:Cross Reactions; D006168:Guinea Pigs; D006220:Haloperidol / Q000097:blood*; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D011863:Radioimmunoassay / Q000379:methods*; D014614:Vaccines, Synthetic / Q000276:immunology
D007106:Immune Sera; D014614:Vaccines, Synthetic; D006220:Haloperidol